ClinicalTrials.gg
CompletedNCT01590199MACS2002Updated Apr 16, 2019

Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

A Phase 1 interventional study of RAD001 and SOM230 in Neuroendocrine Tumors, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing everolimus in Neuroendocrine Tumors — 1 open to participants now, 2 under way, none of them phase 3. Everolimus · Neuroendocrine Tumors.

Enrollment
18th of 22
18 · median 38
Started
2012
with 3 others
Phase 1
6 of 22
none open now
Registered
11th of 22
by date
Lead sponsor
8 of 22
Novartis Pharmaceuticals

Among the 22 studies testing everolimus in Neuroendocrine Tumors, this one is the 18th largest by enrollment, is one of 4 that started in 2012, is one of 6 in phase 1, and was the 11th registered.

Neuroendocrine Tumors

543 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

1 of the 22 studies testing everolimus in Neuroendocrine Tumors is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing everolimus in Neuroendocrine Tumors, or all of them as a file.
02

Study summary

This study will evaluate long-term safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic NET patients, who who have not progressed during 12 months of combination therapy with pasireotide LAR and everolimus

03

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion and Exclusion Criteria:

Patients eligible for inclusion in this extension study have to meet all of the additional inclusion criteria:

  • The patient must provide a signed Form (ICF) for the extension study prior to any study related procedures
  • Completion of the whole treatment period of 15 months (3 months monotherapy with either pasireotide LAR or everolimus followed by a 12 months combination of pasireotide LAR/everolimus) in the CSOM230F2102 study
  • No tumor progression during 12 months of combination therapy with pasireotide LAR and everolimus (checked via radiologically assessment).

No intolerable toxicity during combination therapy with pasireotide LAR and everolimus

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    RAD001 + SOM230

    Drug: RAD001 · Drug: SOM230

Interventions

  • DrugRAD001

    Also known as: Everolimus

  • DrugSOM230

    Also known as: Paseriotide

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events and Serious Adverse Enents as a Measure of Safety and Tolerability

    Time frame: up to 4 years

  2. Number of Participants with abnormal laboratory and ECG results as a Measure of Safety and Tolerability

    Time frame: up to 4 years

Secondary outcomes

  1. investigator-assessed progression free survival (PFS)

    Time frame: up to 4 years

  2. best overall response

    Time frame: up to 4 years

07

Study locations

3 sites
  • Novartis Investigative Site
    Bad Berka, 99438, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Sep 2018, 75 months.

Of 54 phase 1 interventional studies under Neuroendocrine Tumors, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 75. This study's 75 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2012
First posted
May 2, 2012
StartActual
May 18, 2012
Primary completionActual
Sep 11, 2018
CompletionActual
Sep 11, 2018
Last update
Apr 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01590199
Responsible party
Sponsor
First posted
May 2, 2012
Start date
May 18, 2012
Primary completion
Sep 11, 2018
Completion
Sep 11, 2018
Last update
Apr 16, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion